Aptean Signs Partnership With AMT Poland to Drive Growth in European Market
ALPHARETTA, Ga., April 05, 2018 (GLOBE NEWSWIRE) -- Aptean, a leading global provider of mission-critical, industry-specific enterprise software solutions, has formed a strategic partnership with AMT Poland in Gdansk. This partnership will play a critical role in Aptean's continued growth in the European market, specifically Eastern Europe.
AMT will sell and support Aptean's industry-leading Manufacturing Execution System, Aptean Factory MES. Process and discrete manufacturers use Factory MES to gain real-time visibility into production and quality operations, enabling the transition toward a paperless floor. AMT serves its customers in the dynamically growing market for the implementation of industrial automation and modern control systems as well as production management.
"We are very much looking forward to partnering with Aptean and delivering complete end-to-end solutions for our customers. Having focused primarily on automation services, Factory MES will add the missing component to our offering and will help our customers achieve efficient manufacturing and processing operations," said Wojciech Hanuszewski, director of robotics and automation for AMT. "We are excited about this partnership and the opportunity to work with Aptean's products."
AMT's presence as a local reseller in the Polish market will help Aptean better serve its customers in northeastern Europe. In turn, Aptean will rely on AMT's expertise in industrial automation to drive growth in the region.
"There's a growing demand in Europe for forward-thinking technology that gives manufacturers granular visibility into their processes, and to meet that demand, we're expanding Aptean Factory MES across the region," said Alan Somerville, managing director of Aptean EMEA. "AMT's support and expertise will be a great asset in those efforts. We're looking forward to partnering with such a trusted name in the manufacturing technology arena."
AMT Poland's company activity is focused on services for the food industry. Since formation, the company has diversified into the fat or fuel industry. Subsequent years have seen the introduction of industrial robots as part of their service offering. AMT Poland has a wealth of knowledge in technology, in particular technological advances within the food industry.
Aptean provides very specific industries with very specific ERP, supply chain management and customer experience solutions. In today's fast-paced, highly competitive economy, organizations don't have time to waste forcing homegrown software, spreadsheets and one-size-fits-all solutions to do things they were never designed to do. That's why over 7,000 highly specialized organizations in more than 20 industries and 74 countries rely on Aptean to streamline their everyday operations. To learn how Aptean can help your organization stay at the forefront of your industry, visit www.aptean.com.
Aptean is a registered trademark of Aptean, Inc. All other company and product names may be trademarks of the respective companies with which they are associated.
FOR MORE INFORMATION
Stephanie Zercher, Aptean
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aptean via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Despite Brexit Uncertainty, Business Schools in UK Continue to See Strong International Demand19.3.2019 09:00:00 CET | Pressemelding
Majority of Candidates Say Brexit has No Impact on Decision to Study in the United Kingdom RESTON, Va., March 19, 2019 (GLOBE NEWSWIRE) -- In response to the initial Brexit vote in June 2016, the Graduate Management Admission Council™ (GMAC™) has been tracking Graduate Management Admission Test™ (GMAT™) examinee interest in studying in the UK. This has included periodic surveys of non-U.K. citizens who sent a GMAT score report to a UK business school program, as an indication of where they are interested in studying. In the immediate aftermath of the vote, it was unclear what the impact would be on the international flow of students to UK programs, which are heavily reliant on enrollees from other countries. Brexit, it’s been feared, could restrict or complicate the student visa process and dampen international candidates’ postgraduation job prospects in the UK, both because of possible changes to work visa policies and jobs leaving the UK. However, the most recent survey findings, fro
General Electric Company: Doc re. GE files DEFA14A19.3.2019 08:00:00 CET | Pressemelding
FAIRFIELD, Conn., March 19, 2019 (GLOBE NEWSWIRE) -- Company ISIN Symbol Headline General Electric Company US3696041033 London: GEC | Paris: GNE Doc re: GE files DEFA14A March 18, 2019 On March 18, 2019, General Electric Company (the "Company") filed a DEFA14A (Definitive Additional Materials) with the U.S. Securities and Exchange Commission ("SEC"), which has been submitted to the U.K. National Storage Mechanism and will be available shortly for inspection at http://www.morningstar.co.uk/uk/NSM. It is also available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.ge.com/investor-relations/events-reports. CONTACT: GE Jennifer Erickson +001 646 682 5620 firstname.lastname@example.org This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this informatio
General Electric Company: Doc re. GE Files DEF 14A19.3.2019 08:00:00 CET | Pressemelding
FAIRFIELD, Conn., March 19, 2019 (GLOBE NEWSWIRE) -- Company General Electric Company ISIN US3696041033 Symbol London: GEC | Paris: GNE Headline Doc re: GE files DEF 14A March 18, 2019 On March 18, 2019, General Electric Company (the "Company") filed a DEF 14A (Proxy Statement) with the U.S. Securities and Exchange Commission ("SEC"), which has been submitted to the U.K. National Storage Mechanism and will be available shortly for inspection at http://www.morningstar.co.uk/uk/NSM. It is also available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.ge.com/investor-relations/events-reports. CONTACT: GE Jennifer Erickson +001 646 682 5620 email@example.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For
Validated with Microsoft Skype for Business, Patton Delivers Cloud-Powered Integration19.3.2019 05:00:00 CET | Pressemelding
SmartNode ™ VoIP gateways and eSBCs, validated by TekVizion, integrate legacy telephony, ALL-IP communications — or both concurrently — with Skype for Business SmartNode ™ VoIP… More than Just Talk! GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Patton—US-based enabling solutions provider for unified communications (UC), UC-as-a-service (UCaaS) and Cloud—now announces all SmartNode VoIP products version 3.X—including Virtual SmartNode (vSN)—are validated for interoperability with Skype for Business (SfB). SmartNode products are validated by TekVizion, a Microsoft-certified lab, in the SBC and enhanced gateway categories, and are forward compatible with Microsoft Teams. >>Certificate of Validation: Patton SBC/Gateway 3.X Patton Cloud edge orchestration service makes it extra easy to activate, configure and manage the SmartNode-enabled connection with on-premise or hosted Skype for Business. In addition to enabling enterprise transition to ALL-IP using SfB, Patton’s VoIP CPE produ
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results18.3.2019 21:45:00 CET | Pressemelding
On track to initiate Phase 3 VITAL™ trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house Manufacturing scaled to support AAV based programs; GMP readiness expected 2H19 Investor conference call on Tuesday, March 19 at 10:00 a.m. ET NEW YORK and CLEVELAND, March 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced fourth quarter and full year 2018 financial results, and provided business highlights. The Company will host a conference call on Tuesday, March 19 at 10:00 a.m. ET to discuss fourth quarter and full year results, and to provide business highlights. Interested parties are invited to participate in the call by dialing 844-369-8770 (toll-free domestic) or 862-298-0840 (International) or via webcast at https://www.investornetwork.com/event/presentation/44847. “The diligent work conducted over the past nine months
Novavax Reports Fourth Quarter and Year-End 2018 Financial Results18.3.2019 21:05:00 CET | Pressemelding
Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md., March 18, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018. “In 2018, we committed to focus on our two lead programs, ResVax™ and Nanoflu™, and reflecting on last year’s activities, I am proud to say we have achieved significant results for both,” said Stanley C. Erck, President and CEO of Novavax, Inc. “Although we were disappointed to miss the primary endpoint of our Prepare trial, ResVax is the first RSV vaccine to demonstrate efficacy for the prevention of RSV disease in a Phase 3 clinical trial. In addition, the successful Phase 2 results for our NanoFlu vaccine provide an opportunity to now confirm with the FDA the use of accelerated approval for licensure. We are now prepared to make meaningful advances on these programs during 2019.” Fourth Quarter 2018 and Subsequent Opera